Arcline Investment buys majority of Akron Biotechnology

Arcline Investment Management said Sept. 11 that it acquired a majority of Akron Biotechnology LLC. Financial terms weren’t announced. Akron Biotechnology supplies cGMP-compliant products and services for the production of advanced therapy medicinal products, including cell therapies, gene therapies and engineered tissues. BroadOak Capital Partners invested in Akron in 2017, PitchBook said.

DealsNorth AmericaUSHealthcareBriefs